Pathobiology of ALK-negative anaplastic large cell lymphoma

Stefano A. Pileri,¹ Claudio Agostinelli,¹
 Francesco Bacci,¹ Elena Sabattini,¹
 Carlo Sagramoso,¹ Brunangelo Falini,²
 Pier Paolo Piccaluga¹

¹Hematopathology Section, Department of Hematology and Oncological Sciences "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; ²Institute of Haematology, Silvestrini Hospital, University of Perugia, Perugia, Italy

Abstract

The authors revise the concept of ALK-negative anaplastic large cell lymphoma (ALCL) in the light of the recently updated WHO classification of Tumors of Hematopoietic and Lymphoid Tissues both on biological and clinical grounds. The main histological findings are illustrated as well as the phenotypic, molecular and clinical characteristics. Finally, the biological rationale for possible innovative targeted therapies is presented.

Introduction

Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma (PTCL), representing around 2-3% of all lymphoid neoplasms, according to the World Health Organization (WHO) estimates.^{1,2} Originally described by Stein *et al.* in 1985,³ it has undergone a series of revisions, which have led to a more restrictive definition of the process.^{1,2,4,5} In particular, two different entities are recognized as systemic forms, the ALK⁺ and ALK⁻ ALCL,^{1,2,6} the former being characterized by the deregulated expression of chimeric proteins expressing the intracytoplasmic domain of the anaplastic lymphoma kinase (ALK) gene. Noteworthy, in the last edition of the WHO classification, ALK-ALCL was regarded as a provisional entity.^{1,2} However, emerging evidences suggest it represent a distinctive condition.⁷ On the other hand, differently from what initially reported by Stein *et al.*,³ the cutaneous variant was recognized as a different disease.⁸

Morphology

According to the WHO classification, ALK-ALCL, like the ALK⁺ form, includes morphologic variants: common, giant cell-rich, lympho-histiocytic, and Hodgkin-like.^{1,2,9,10} All morphological variants are characterized by a variable

proportion of large hallmark cells with eccentric horse-shoe or kidney shaped nuclei). The giant cell-rich type is characterized by several multinucleated elements, often provided with Reed-Sternberg-like features and prominent intra-sinusoidal diffusion.^{1,5,11,12} The lympho-histiocytic variant displays a marked variability of the neoplastic cell size that ranges from small to large. These are almost obscured by abundant reactive histiocytes with eccentric nuclei, a finding that can lead to a misdiagnosis of hyper-immune reaction.^{1,2,9,13-15} Interestingly, transition from one histotype to the other is at times recorded within the same node (mixed variant) or in different nodes taken from the same patient at the time of diagnosis or in relapse: these modifications might correspond to intra-clonal modulation or different interaction between the tumor and micro-environment.^{9,16} Finally, the so-called ALCL of the Hodgkin-like type deserves special attention.¹⁷ It was originally described as a form of the tumor, presenting in young people with a bulky mediastinal mass and consisting of anaplastic cells arranged in nodules surrounded by sclerotic bands, as seen in nodular sclerosing Hodgkin's lymphoma (NSHL).¹⁷ Following the introduction of the REAL Classification,⁵ which regarded it as a provisional entity, such diagnosis was by no means also applied to cases of aggressive HL that could not be easily differentiated from ALCL, both on morphologic and phenotypic grounds.⁵ This led to a diffuse skepticism on the existence of such variant: it was considered a basket more than an entity. However, although rare, *bona fide* examples of ALK⁻ ALCL of the Hodgkin-like type can be encountered. These are characterized by homogeneous CD30-positivity, lack of CD15 and B-cell activator protein (BSAP), variable expression of T-cell antigens, CD45 and epithelial membrane antigen (EMA), Epstein-Barr virus (EBV) negativity and clonal TCR gene rearrangement.

Phenotype

Neoplastic cells of ALK⁻ ALCL carry a distinctive phenotypic profile irrespectively of the histotype.^{1,2,11,18} They regularly express CD30,^{1-3,19} a glycoprotein of 120 kD carried by lymphoid elements following activation. At immunohistochemical analysis, the antibodies against CD30 produce different types of positivity: membrane-bound, dot-like in the Golgi area (corresponding to the accumulation of the 90 kD proteic precursor), and diffuse.¹⁹ The first two patterns are exclusive of lymphoid elements with the exception of embryonic carcinoma,¹⁹ while the third one can at times occur in a variety of malignant tumors other than lymphomas.¹⁹ Therefore, the immunophenotypic diagnosis of ALCL should always be based on the application of a panel of antibodies, including reagents anti-cytokeratins, melanoma-associated antigens, CEA, and PLAP.^{1,2} In 60-

Correspondence: Stefano A. Pileri, Department of Hematology and Oncological Sciences "L. and A. Seràgnoli", University of Bologna, S. Orsola-Malpighi Hospital, Pavillon 8, Via Massarenti 9, 40138 Bologna, Italy. Tel: +39-051-6363044 - Fax: +39-051-6363606. E-mail: stefano.pileri@unibo.it

Key words: ALK-negative anaplastic large cell lymphoma.

Financial disclosure: the authors have no conflicting financial interests to declare.

Acknowledgements: this work was supported by grants from Centro Interdipartimentale per la Ricerca sul Cancro "G. Prodi", Bologna, Ateneo 60% (Prof. S.A. Pileri), FIRB (Prof. S.A. Pileri and Prof. P.L. Zinzani), AIRC (10007, 10519), Fondazione CARISBO, Progetto Strategico d'Ateneo (Prof. S.A. Pileri, Dr. P.P. Piccaluga).

Received for publication: 4 May 2011.
 Accepted for publication: 4 June 2011.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright S.A. Pileri *et al.*, 2011
 Licensee PAGEPress, Italy
 Pediatric Reports 2011; 3(s2):e5
 doi:10.4081/pr.2011.s2.e5

70% of cases, ALK⁻ ALCL carries the EMA.^{9,20} CD3 expression is appreciated in about half cases: it usually occurs at the cytoplasmic level as expected in activated cells.^{9,21} CD3⁺ tumors may carry CD2, CD5 and/or CD7.^{9,11,21-23} The expression of CD4 and CD8 is variable.^{9,11} Positivity for TIA-1, granzyme B and perforin is recorded in most instances. About 20% of ALCL lack CD45 and/or express CD15.⁹ Notably, BSAP (i.e. the PAX5 gene product) is absent:²⁴ its search represents a very useful tool for the differentiation of ALK⁻ ALCL from HL and DLBCL, which are both BSAP-positive.²⁴ Finally, the search for EBV turns negative in ALK-ALCLs both by *in situ* hybridization (ISH) and immunohistochemistry: such negativity is regarded as one of the distinguishing features between ALCL and HL in controversial cases.²⁵

Molecular genetics

Recently, by using a comparative genomic hybridization (CGH) platform, Salaverria *et al.*²⁶ identified chromosomal imbalances in 65% of ALK⁻ cases, within a cohort of 31 tumors. In particular, gains of 1q and 6p21 were more frequently observed.²⁶ Interestingly, few recurrent chromosomal imbalances were found in common with ALK⁺ ALCL (gains of 7 and 6q and 13q losses), confirming that all ALCLs probably share common pathogenetic events (see below).

As far as gene expression profiling (GEP) is concerned, Thompson *et al.*²⁷ initially demonstrated the ability of GEP to correctly distinguish between ALK⁺ and ALK⁻ ALCL based on the analysis of their transcriptome and suggested that some pathogenetic mechanisms might be shared by these two entities, basing on the common expression of certain genes in both ALK⁺ and ALK⁻ cases.

Subsequently, Lamant *et al.*²⁸ confirmed that the different morphological variants as well as ALK⁺ and ALK⁻ ALCL could be distinguished based on the expression of specific genes. Specifically, ALK⁻ ALCL were found to over-express *CCR7*, *CNTFR*, *IL22* and *IL21*.

Our group then included some ALCL in a GEP study on PTCLs.²⁹ Interestingly, we found that ALCL can be roughly distinguished from other PTCLs irrespectively of the ALK status, confirming the idea of common pathogenetic events. Finally, Piva *et al.*⁷ showed, that ALCL are molecularly distinct from PTCL/NOS. To this regard, grippingly, a predictive analysis allowed to identify 34 probe sets capable to distinguish ALCL from other PTCLs. Furthermore, it was possible to clearly differentiate ALK⁺ and ALK⁻ cases according to their GEPs, basing on the expression of selected genes, including *GAS1*, an ALK dependent molecule.⁷

More recently, Eckerle *et al.*²³ studied isolated cells from ALCL cases. Interestingly, the analysis supported the derivation of ALCL from activated T cells, though it was not possible to identify a specific counterpart. Surprisingly, only few genes were differentially expressed between systemic and cutaneous ALCL despite their different clinical behavior, and between ALK⁻ ALCL and classical Hodgkin lymphoma, despite their different cellular origin.²³

Clinical behavior

ALK⁻ ALCL is an aggressive lymphoma which frequently presents in advanced clinical stage (III-IV) with B-symptoms, and extra-nodal involvement, as other PTCLs do.^{11,30} Bone marrow involvement is detected in up to 30% of cases, being a relevant prognostic feature.³¹⁻³³

Importantly, ALCL display quite different clinical features depending on the expression or not of the ALK protein.^{6,11,30,34-36} ALK⁻ tumors are usually recorded among people aged 50-70,^{6,11,30} and, most importantly, ALK⁺ has a significantly better outcome than ALK⁻ ALCL. In particular, up to 90% of ALK⁺ ALCL achieve complete remission (CR) by adopting standard anthracyclin-containing regimens, and 70-80% of patients were actually cured.^{6,11,30,34-36} By contrast, only around 30-50% of ALK⁻ cases obtain stable CR by the same therapies,^{6,11,30} suggesting that more aggressive strategies including autologous or allogeneic bone-marrow/stem cell transplantation may be necessary.³⁷

Noteworthy, the International T-cell lymphoma project have recently reported that

ALK⁺ and ALK⁻ ALCL seem to have a similar prognosis (in terms of both FFS and OS), when patients are stratified according to the clinical parameters (i.e. age and/or stage). Grippingly, this would suggest a prominent role for clinical factors in determining patients outcome, rather than for biological components.⁶

Notably, in the past years, it was suggested that the distinction between ALK⁻ ALCL and PTCL/NOS was of limited clinical relevance, only age and the International Prognostic Index (IPI) being of prognostic relevance in these tumors.³⁸ Nevertheless, it was recently shown that clinical differences do exist between the two entities. In particular, in a large international study, a greater proportion of patients with poor performance status and B-symptoms, but a lower frequency of bone marrow invasion, splenic involvement and thrombocytopenia were observed in ALK⁻ ALCL as compared to PTCL/NOS.⁶ Indeed, in this study, ALK⁻ ALCL showed an overall outcome significantly better than PTCL/NOS.⁶

Targeted therapy

Importantly, as tyrosine-kinase deregulation has been documented in several PTCLs,^{29,39-41} it is conceivable that ALK⁻ ALCL might present similar phenomenon as well, further studies being indeed warranted.

Finally, immunotherapy strategies could represent another possible therapeutic approaches. In particular, *in vitro* and *in vivo* studies showed that anti-CD30 antibodies induce apoptotic cell death and tumor regression in CD30⁺ lymphomas, including ALCL.⁴²⁻⁴⁶ In addition, other studies have suggested that CD26 might represent a promising immunotherapeutic target.⁴⁷

Conclusions

Although ALK⁻ ALCL is still quoted as a provisional entity, increasing evidences, both biological and clinical, suggest that it actually represent a tumor with distinctive features.

References

1. Delsol G, Jaffe ES, Falini B, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow S, Campo E, Harris NL, et al., eds. WHO Classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC, 2008:312-16.
2. Mason DY, Harris NL, Delsol G, et al. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow S, Campo E, Harris NL, et al., eds. WHO Classification of tumors of hematopoietic and lymphoid tissues. Lyon:

IARC, 2008:317-19.

3. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. *Blood* 1985;66:848-58.
4. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. *Lancet* 1988;1:292-3.
5. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994;84:1361-92.
6. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK⁺ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood* 2008;111:5496-504.
7. Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *J Clin Oncol* 2010;28:1583-90.
8. Ralfkiaer E, Willemze R, Pauli M, et al. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow S, Campo E, Harris NL, et al., eds. WHO Classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC, 2008:300-01.
9. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. *Blood* 1998;91:2076-84.
10. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. *Mod Pathol* 2001;14:219-28.
11. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. *Blood* 2000;96:3681-95.
12. Kadin ME. Anaplastic large cell lymphoma and its morphological variants. *Cancer Surv* 1997;30:77-86.
13. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. *Am J Pathol* 1998;153:875-86.
14. Pileri SA, Pulford K, Mori S, et al. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. *Am J Pathol* 1997; 150:1207-11.
15. Piccaluga PP, Ascani S, Fraternali Orcioni G, et al. Anaplastic lymphoma kinase expression as a marker of malignancy. Application to a case of anaplastic large cell lymphoma with huge granulomatous reaction. *Haematologica* 2000;85:978-81.

16. Hodges KB, Collins RD, Greer JP, et al. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: pathologic and clinical features. *Am J Surg Pathol* 1999;23:49-58.
17. Vassallo J, Lamant L, Brugieres L, et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: report of 10 cases. *Am J Surg Pathol* 2006;30:223-9.
18. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. *Br J Haematol* 2001;114:741-60.
19. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. *Blood* 1995;85:1-14.
20. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. *Am J Pathol* 1988;130:59-70.
21. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. *Blood* 2004;104:3358-60.
22. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. *Am J Surg Pathol* 2003;27:1513-22.
23. Eckerle S, Brune V, Doring C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. *Leukemia* 2009;23:2129-38.
24. Agostinelli C, Sabattini E, Gyorret JO, et al. Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples. *Appl Immunohistochem Mol Morphol* 2010;18:561-72.
25. Brousset P, Rochaix P, Chittal S, et al. High incidence of Epstein-Barr virus detection in Hodgkin's disease and absence of detection in anaplastic large-cell lymphoma in children. *Histopathology* 1993;23:189-91.
26. Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. *Br J Haematol* 2008;140:516-26.
27. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. *Hum Pathol* 2005;36:494-504.
28. Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. *Blood* 2007;109:2156-64.
29. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. *J Clin Invest* 2007;117:823-34.
30. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. *Blood* 1999;93:2697-706.
31. Fraga M, Brousset P, Schlaifer D, et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. *Am J Clin Pathol* 1995;103:82-9.
32. Mussolin L, Pillon M, d'Amore ES, et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. *Leukemia* 2005;19:1643-7.
33. Kalinova M, Krskova L, Brizova H, et al. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma—residual disease monitoring and a correlation with the disease status. *Leuk Res* 2008;32:25-32.
34. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. *Blood* 1995;86:1954-60.
35. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. *Ann Oncol* 1997;8:583-92.
36. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol* 2008;26:4124-30.
37. d'Amore F, Jantunen E, Relander T. Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how? *Curr Hematol Malig Rep* 2009;4:236-44.
38. ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. *Histopathology* 2003;43:462-9.
39. Piccaluga PP, Agostinelli C, Zinzani PL, et al. Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. *Lancet Oncol* 2005;6:440.
40. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. *Cancer Res* 2007; 67:10703-10.
41. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal-type. *Blood* 2010;115:1226-37.
42. Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. *Lancet* 1992;339:1195-6.
43. Tazzari PL, Bolognesi A, de Toter D, et al. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. *Br J Haematol* 1992;81:203-11.
44. Pasqualucci L, Wasik M, Teicher BA, et al. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. *Blood* 1995;85:2139-46.
45. Pfeifer W, Levi E, Petrogiannis-Halioitis T, et al. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). *Am J Pathol* 1999;155:1353-9.
46. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. *Drugs* 2007;67:333-50.
47. Ho L, Aytac U, Stephens LC, et al. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. *Clin Cancer Res* 2001;7:2031-40.